UNICYCIVE THERAPEUTICS, INC. Interest Expense
UNICYCIVE THERAPEUTICS, INC. (UNCY) reported Interest Expense of $20.00 thousand for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-13.
Discontinued › Expense Statement
us-gaap:InterestExpense · last filed 2024-05-13
- UNICYCIVE THERAPEUTICS, INC. interest expense for the quarter ending 2024-03-31 was $20.00K, a 66.67% increase year-over-year.
- UNICYCIVE THERAPEUTICS, INC. interest expense for the quarter ending 2023-12-31 was $19.00K, a 533.33% increase year-over-year.
- UNICYCIVE THERAPEUTICS, INC. interest expense for the quarter ending 2023-09-30 was $18.00K, a 500.00% increase year-over-year.
- UNICYCIVE THERAPEUTICS, INC. interest expense for the quarter ending 2023-06-30 was $32.00K.
- UNICYCIVE THERAPEUTICS, INC. interest expense for fiscal 2023 was $82.00K, a 1266.67% increase from fiscal 2022.
- UNICYCIVE THERAPEUTICS, INC. interest expense for fiscal 2022 was $6.00K, a 99.04% decline from fiscal 2021.
- UNICYCIVE THERAPEUTICS, INC. interest expense for fiscal 2021 was $628.00K, a 157.38% increase from fiscal 2020.
- UNICYCIVE THERAPEUTICS, INC. interest expense for fiscal 2020 was $244.00K.
| Period end | Interest Expense 3 month | Interest Expense 6 month | Interest Expense 9 month | Interest Expense 12 month |
|---|---|---|---|---|
| 2024-03-31 | $20.00K 10-Q · filed 2024-05-13 | $39.00K derived: sum of 2 quarters · filed 2024-05-13 | $57.00K derived: sum of 3 quarters · filed 2024-05-13 | $89.00K derived: sum of 4 quarters · filed 2024-05-13 |
| 2023-12-31 | $19.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $37.00K derived: sum of 2 quarters · filed 2024-03-28 | $69.00K derived: sum of 3 quarters · filed 2024-03-28 | $82.00K 10-K · filed 2024-03-28 |
| 2023-09-30 | $18.00K 10-Q · filed 2023-11-14 | $50.00K derived: sum of 2 quarters · filed 2023-11-14 | $63.00K 10-Q · filed 2023-11-14 | $65.00K derived: sum of 4 quarters · filed 2024-05-13 |
| 2023-06-30 | $32.00K 10-Q · filed 2023-08-14 | $44.00K 10-Q · filed 2023-08-14 | $47.00K derived: sum of 3 quarters · filed 2024-05-13 | $50.00K derived: sum of 4 quarters · filed 2024-05-13 |
| 2023-03-31 | $12.00K 10-Q · filed 2024-05-13 | $15.00K derived: sum of 2 quarters · filed 2024-05-13 | $18.00K derived: sum of 3 quarters · filed 2024-05-13 | |
| 2022-12-31 | $3.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $6.00K derived: sum of 2 quarters · filed 2024-03-28 | $6.00K 10-K · filed 2024-03-28 | |
| 2022-09-30 | $3.00K 10-Q · filed 2023-11-14 | $3.00K 10-Q · filed 2023-11-14 | ||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $55.00K derived: sum of 2 quarters · filed 2023-03-31 | $376.00K derived: sum of 3 quarters · filed 2023-03-31 | $628.00K 10-K · filed 2023-03-31 |
| 2021-09-30 | $55.00K 10-Q · filed 2022-11-14 | $376.00K derived: sum of 2 quarters · filed 2022-11-14 | $628.00K 10-Q · filed 2022-11-14 | $791.00K derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $321.00K 10-Q · filed 2022-08-15 | $573.00K 10-Q · filed 2022-08-15 | $736.00K derived: sum of 3 quarters · filed 2022-08-15 | $812.00K derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | $252.00K 10-Q · filed 2022-05-12 | $415.00K derived: sum of 2 quarters · filed 2022-05-12 | $491.00K derived: sum of 3 quarters · filed 2022-05-12 | $493.00K derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $163.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $239.00K derived: sum of 2 quarters · filed 2022-03-31 | $241.00K derived: sum of 3 quarters · filed 2022-03-31 | $244.00K 10-K · filed 2022-03-31 |
| 2020-09-30 | $76.00K 10-Q · filed 2021-11-12 | $78.00K derived: sum of 2 quarters · filed 2021-11-12 | $81.00K 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $2.00K 10-Q · filed 2021-08-16 | $4.00K 10-Q · filed 2021-08-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |